Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Cifenline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 1/20 | 0.79 |
| ▸ | AR | P10275 | 1/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | SCN1A | P35498 | 1/20 | 0.79 |
| ▸ | SCN4A | P35499 | 1/20 | 0.79 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.79 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.79 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.79 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.79 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.79 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.79 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.79 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.79 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.79 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cifenline SCHEMBL122806 | 0.89 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL23712302 | 0.89 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL23712274 | 0.89 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL29387230 | 0.87 | CACNA1F (0.79) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL28086532 | 0.70 | CACNA1F (0.55) | CACNA1FARPDE4ASCN1ASCN4A | |
| Tolazoline SCHEMBL28268861 | 0.66 | TAAR1 (0.78) | KCNH2ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL10468078 | 0.64 | LMNA (0.41) | MAOBALDH1A1OPRM1CYP2D6 | |
| SCHEMBL10468077 | 0.64 | LMNA (0.41) | MAOBALDH1A1OPRM1CYP2D6 | |
| SCHEMBL10468076 | 0.64 | LMNA (0.41) | MAOBALDH1A1OPRM1CYP2D6 | |
| Succinic Acid SCHEMBL28852957 | 0.61 | OPRM1 (0.46) | ALDH1A1OPRM1CYP3A4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486237-B2 | Polymorphic form of (-)-cibenzoline succinate | CELLTRION INC. (KR) | 2025-12-02 | — | — | US | claimed |
| US-20240074968-A1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2024-03-07 | — | — | US | claimed |
| EP-4279137-A2 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | Sunsho Pharmaceutical Co., Ltd. (JP) | 2023-11-22 | — | — | EP | claimed |
| EP-3485876-B1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2023-11-22 | — | — | EP | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| US-20230088511-A1 | Polymorphic Form of (-)-Cibenzoline Succinate | CELLTRION INC. (KR) | 2023-03-23 | — | — | US | claimed |
| EP-3858816-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2021-08-04 | — | — | EP | claimed |
| US-20200315962-A1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-08 | — | — | US | claimed |
| WO-2020067684-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | (주)셀트리온 | 2020-04-02 | — | — | WO | claimed |
| EP-3485876-A1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | Sunsho Pharmaceutical Co., Ltd. (JP) | 2019-05-22 | — | — | EP | claimed |
| CN-107353228-A | A kind of preparation method of cibenzoline succinate intermediate | 辅仁药业集团熙德隆肿瘤药品有限公司 | 2017-11-17 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12486237-B2 | Polymorphic form of (-)-cibenzoline succinate | CELLTRION INC. (KR) | 2025-12-02 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-4892742-A | TABLET CORE CONTAINING A DRUG AND POLYMER MATRIX SURROUNDED WITH A RATE CONTROLLING MEMBRANE COATING | HOFFMANN-LA ROCHE INC. (US) | 1990-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | ME2, TNNT2, TNNC1 | CACNA1F 292/4885AR 3630/4885PDE4A 3415/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | CACNA1F 386/4885AR 1072/4885PDE4A 1773/4885 |
| US-20230088511-A1 | Polymorphic Form of (-)-Cibenzoline Succinate | SDHA, SDHB, ALDH5A1 | CACNA1F 300/4885AR 2420/4885PDE4A 1992/4885 |
| US-12486237-B2 | Polymorphic form of (-)-cibenzoline succinate | SDHA, SDHB, ALDH5A1 | CACNA1F 308/4885AR 2526/4885PDE4A 1892/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | CACNA1F 32/4885AR 2897/4885PDE4A 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.